Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹æ±¤ÀÌÇà»óÇǾϿ¡¼­ bel-2, p53 ´Ü¹éÁú ¹ßÇöÀÇ ºñ±³ Correlation of bel-2 and p53 Expressions in Urinary Bladder Tumor

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 6È£ p.703 ~ 708
À̱æÈ£, À̹Îö, ±èÇüÁö,
¼Ò¼Ó »ó¼¼Á¤º¸
À̱æÈ£ (  ) 
´Ü±¹´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°ú±³½Ç

À̹Îö (  ) 
´Ü±¹´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
±èÇüÁö (  ) 
´Ü±¹´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°ú±³½Ç

Abstract

¼­·Ð
Ç¥À缺¹æ±¤¾ÏÀÇ 10%´Â Áø´Ü ÈÄ 3³â À̳» ħÀ±¼º Á¾¾çÀ¸·Î ÁøÇàµÈ´Ù. ³ôÀº ºÐÈ­µµ, Á¡¸·°í
À¯ÃþÀÇ Ä§À± µîÀÇ º´¸®ÇÐÀû ¼Ò°ß°ú Á¾¾çÀ¯¹ßÀ¯ÀüÀÚ¿Í Á¾¾ç¾ïÁ¦À¯ÀüÀÚÀÇ ¼Ò½Ç µî°ú °°Àº ¿©
·¯ ¿¹ÈÄ ÀÎÀÚµéÀÌ Ä§À±¿¡ °ü¿©ÇÑ´Ù. p53Àº Á¾¾ç¾ïÁ¦À¯ÀüÀÚ·Î ±â´ÉÇÏ´Ù°¡ ÀϺΠ¿°±â¼­¿­¿¡
º¯È­°¡ ¹ß»ýµÇ¸é ±× °íÀ¯ ±â´ÉÀÇ ¼Ò½Ç·Î Á¾¾ç¹ß»ý¿¡ À¯¸®ÇÑ Á¶°ÇÀÌ µÈ´Ù. ´ëÀå¾Ï 70%, À¯¹æ
¾Ï 30-50%, Æó¾Ï 50%Á¤µµ¿¡¼­ P53 À¯ÀüÀÚ µ¹¿¬º¯ÀÌ°¡ °üÂûµÇ¾î Áö±Ý±îÁö ¾Ë·ÁÁø ´ëÇ¥ÀûÀÎ
Á¾¾çÀ¯¹ßÀ¯ÀüÀÚÀÌ´Ù. ¶ÇÇÑ p53 µ¹¿¬º¯ÀÌ°¡ ÀÖ´Â °æ¿ì ´õ °ø°ÝÀûÀÎ Á¾¾çÀ¸·Î ¹ßÀüÇÏ°í ±× ¿¹
ÈÄ°¡ ³ª»Û °ÍÀ¸·Î ¾Ë·ÁÁ³´Ù. Habuchi µîÀº ħÀ±¼º ¹æ±¤Á¾¾ç¿¡¼­ p53 µ¹¿¬º¯À̸¦ °üÂûÇÒ ¼ö
ÀÖ´Ù°í ÇÏ¿© p53 À¯ÀüÀÚ´Â ¹æ±¤Á¾¾çÀÇ ¹ß»ýº¸´Ù´Â Á¾¾çÀÇ ÁøÇà°ú ¿¹ÈÄ¿Í °ü·ÃÀÌ ÀÖ´Ù°í ÇÏ
¿´À¸³ª Schmitz-DragerµîÀº ¹æ±¤»óÇÇÀÌÇü¼ºÁõÀ̳ª »óÇdz»¾ÏÁ¾ µî ¹æ±¤Á¾¾ç Ãʱ⺴º¯¿¡µµ
p53 ´Ü¹éÁúÀº ¿°»öµÈ´Ù°í ÇÏ¿© P53 À¯ÀüÀÚ´Â ¹æ±¤Á¾¾çÀÇ ¹ß»ý Ãʱ⿡ °ü¿©ÇÑ´Ù´Â ÁÖÀåµµ
ÀÖ´Ù.
bel-2 À¯ÀüÀÚ´Â ¼¼Æ÷°í»ç(apoptosis)¸¦ ¾ïÁ¦ÇÏ¿© º¯ÀÌµÈ Á¾¾ç¼¼Æ÷ºñ Áõ½Ä°ú ÀüÀÌ, Ç×¾Ï Ä¡
·á¿¡ ÀúÇ× µî¿¡ °ü¿©ÇÑ´Ù°í ÇÏ¿© Á¾¾ç¿¡¼­ bcl-3ÀÇ ¹ßÇöÀº ¿¹ÈÄ°¡ ³ª»Ü °ÍÀ¸·Î ÃßÁ¤ÇÒ ¼ö
ÀÖÀ¸³ª ÃÖ±Ù¿¡´Â Áö±Ý±îÁö ¾Ë·ÁÁø °Í°ú ´Ù¸£°Ô À¯¹æ¾Ï, Æó¾Ï, ºñÈ£Ã÷Ų½ºÀÓÆÄÁ¾ µî¿¡¼­
bcl-2ÀÇ °ú¹ßÇöÀº ¿¹ÈÄ°¡ ÁÁ°í p53°ú bcl-2ÀÇ »óÈ£ÀÛ¿ëµµ ¶ÇÇÑ ³í¶õÀÌ ¸¹´Ù.
º» ¿¬±¸ÀÇ ¸ñÀûÀº ¹æ±¤¾Ï¿¡¼­ »ç¸êÀÛ¿ëÀÇ ¾ïÁ¦ÀÎÀÚÀÎ bcl-3¿Í P53 ´Ü¹éÁúÀÇ »ó°ü°ü°è¸¦
±Ô¸íÇÏ°í ÀÌµé ´Ü¹éÁú°ú Åë»óÀûÀ¸·Î ¿¹ÈÄ ÀÎÀÚ·Î ¾Ë·ÁÁø Á¾¾çºÐÈ­µµ¿Í Á¾¾çº´±â¿Í ºñ±³ÇÏ¿©
¹æ±¤Á¾¾ç ¹ß»ý°ú Á¾¾ç ÁøÇà¿¡ ÀÌµé ´Ü¹éÁúÀÇ ¿ªÇÒÀ» ±Ô¸íÇϴµ¥ ÀÖ´Ù.

Purpose: Alteration of p53 tumor suppressor genes is most frequently identified in
human neoplasms, including urinary bladder tumor. The overexpression of the bel-2
gene has been correlated with poor prognosis and chemotherapy resistance in other
systems. We evaluated the significance of these gene expressions and correlation with
prognostic factors in the urinary bladder cancer.
Materials and Methods: The expression of bcl-2 and p53 oncoprotein were
investigated serially in formalin-fixed and paraffin-embedded tissue specimens from 43
patients with primary transitional cell carcinoma in the urinary bladder. Thirsty four
were superficial bladder tumors and nine were invasive tumors. In histology grade
according to WHO grading there were 9 grade ¥°, 21 grade ¥± and 13 grade ¥².
Results: Positive immunoreaction for bel-2 was found In 3 out of 9 invasive bladder
tumors, while 15 of 34 superficial tumors showed positive staining. Positive p53
immunostaining was found in 7 of 9 invasive tumors, while 18 of 34 superficial tumors
showed positive staining. There was no significant correlation between bcl-2 or p53
expression and tumor stage(p=0.56, p=0.179). A higher incidence of bel-2 staining was
found in the grade ¥° group than In the grade ¥² group(p=0.041). There was no
significant correlation between p53 expression and tumor grade(p=0.23). A significant
inverse relationship was found between bcl-2 and p53 topographic expression(p=0.001).
Conclusions: The results of this study indicated an inverse relationship between bcl-2
and p53 expression. These findings suggest bcl-2 expression may be associated with
favorable prognosis in bladder tumor.

Å°¿öµå

Bladder tumor; bel-2; p53; Immunohistochemical staining;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS